Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

The global cell and gene therapy biomanufacturing market is projected to grow from $12.35 billion in 2025 to $13.83 billion in 2026, a compound annual growth rate of 12%, and to reach $21.46 billion by 2030 at a compound annual growth rate of 11.6% from 2026, according to the Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026 added to ResearchAndMarkets.com. Growth is being driven by the increasing commercialization of cell and gene therapies, demand for scalable viral vector production, wider adoption of personalized medicine, and expansion among contract development and manufacturing organizations, alongside automation, digitalization, and investment in modern biomanufacturing facilities. The report cites the American Society of Gene and Cell Therapy's finding that the number of gene therapies in Phase III development increased by 10% during the fourth quarter of 2023 compared with the previous quarter, the first quarterly increase since the third quarter of 2022. In May 2026, Andelyn Biosciences launched its LVV Curator platform to streamline lentiviral vector manufacturing, using a modular, prevalidated framework based on Curator methodology previously applied across more than 100 adeno-associated virus programs. In January 2024, Oxford Biomedica plc acquired ABL Europe SAS for $17.35 million, expanding its manufacturing presence in Europe and its viral vector development and production services. North America was the largest cell and gene therapy biomanufacturing market in 2025, while Asia-Pacific is forecast to be the fastest-growing region; companies featured include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and Samsung Biologics Co. Ltd.

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.